Clinical efflcacy and safety of treprostinil combination treatment for pulmonary hypertension

WANG Lin; GUO Jun; WANG Guangyi; CHEN Yundai

Abstract：Objective To observe the long-term effects and safety of treprostinil combined with bosentan in treating pulmonary hypertension. Methods Thirty-two patients who were hospitalized for pulmonary hypertension between November 2014 and November 2015 were selected and divided into 2 groups: the combined group (16 cases) and the control group (16 cases). For the control group treatment, bosentan 62.5 mg bid was taken orally, and was increased to 125 mg bid in two weeks. For the combined therapy group, the patients were given Remodulin by subcutaneous injection combined with bosentan. The initial drug dose was 0.625 ng/(kg·min) calculated according to a patient's weight, and the dose was adjusted according to the condition of the patient and adverse reactions. The dose ranged from 0.3 ng/(kg·min) to 8.75 ng/(kg·min). Then, the changes of some of the clinical indexes, such as pulmonary artery systolic pressure (PASP), 6-minute walk distance (6MWD) and the WHO functional class, were evaluated after 24 weeks of treatment. Results The WHO functional class, 6MWD, Borg dyspnea score and mixed venous oxygen saturation were improved significantly (P<0.05). The PASP and N-terminal pro-brain natriuretic peptide were decreased, but without statistically significant difference (P>0.05). There was no significant difference in the incidence of adverse reactions between the combined group and the control group (P>0.05). Conclusion Remodulin combined with bosentan for severe pulmonary hypertension can not only improve the heart function and the ability to move about, but is safe.